Enzyme replacement therapy for lysosomal storage disorder patients

J. Hopwood

Research output: Contribution to journalArticle

Abstract

There are 38 known genetic diseases that lead to a breakdown in lysosome function and the pathological storage of substrates in lysosomes. These disorders are known as lysosomal storage disorders (LSD). The importance of LSD to health care becomes obvious when the group incidence rate for LSD (at least 1:5,000) is compared with well-known and intensively studied genetic disorders such as cystic fibrosis (1:2,500) and PKU (1:15,000). All LSD result from a deficiency of enzymes that are involved in the degradation of macromolecules (such as mucopolysaccharides, glycolipids, glycoproteins) or the transport of the products of degradation (such as amino acid, monosaccbarides and inorganic sulphate) out of the lysosome to be recycled. The deficiency of a particular enzyme activity results in lysosomal storage of the substrate for that enzyme. A number of therapies are currently in use or are under evaluation for various LSD types. Bone marrow transplantation has been tried for a number of LSD with some, but limited success. Gene therapy trials for some LSD patients are planned. However, the most effective therapy so far has been enzyme replacement (ERT) for Gaucher disease (a glycolipid LSD). We have been developing ERT for a group of LSD known as the mucopolysaccharidoses (MPS). There are 10 different MPS and we have prepared recombinant enzymes for MPS types I, II, IIIA, IIIB, IIID, IVA and VI. Preliminary results with MPS-VI cats treated with human recombinant N-acetylgalactosamine-4-sulphatase have been most encouraging. We anticipate clinical trials for some of these MPS conditions within a year or two.

LanguageEnglish
Pages157-158
Number of pages2
JournalAustralian Journal of Medical Science
Volume17
Issue number4
Publication statusPublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{1d6ff3c33e4d480b8d6e074b2bec6a0d,
title = "Enzyme replacement therapy for lysosomal storage disorder patients",
abstract = "There are 38 known genetic diseases that lead to a breakdown in lysosome function and the pathological storage of substrates in lysosomes. These disorders are known as lysosomal storage disorders (LSD). The importance of LSD to health care becomes obvious when the group incidence rate for LSD (at least 1:5,000) is compared with well-known and intensively studied genetic disorders such as cystic fibrosis (1:2,500) and PKU (1:15,000). All LSD result from a deficiency of enzymes that are involved in the degradation of macromolecules (such as mucopolysaccharides, glycolipids, glycoproteins) or the transport of the products of degradation (such as amino acid, monosaccbarides and inorganic sulphate) out of the lysosome to be recycled. The deficiency of a particular enzyme activity results in lysosomal storage of the substrate for that enzyme. A number of therapies are currently in use or are under evaluation for various LSD types. Bone marrow transplantation has been tried for a number of LSD with some, but limited success. Gene therapy trials for some LSD patients are planned. However, the most effective therapy so far has been enzyme replacement (ERT) for Gaucher disease (a glycolipid LSD). We have been developing ERT for a group of LSD known as the mucopolysaccharidoses (MPS). There are 10 different MPS and we have prepared recombinant enzymes for MPS types I, II, IIIA, IIIB, IIID, IVA and VI. Preliminary results with MPS-VI cats treated with human recombinant N-acetylgalactosamine-4-sulphatase have been most encouraging. We anticipate clinical trials for some of these MPS conditions within a year or two.",
author = "J. Hopwood",
year = "1996",
language = "English",
volume = "17",
pages = "157--158",
journal = "Australian Journal of Medical Science",
issn = "1038-1643",
publisher = "Australian Institute of Medical Scientists",
number = "4",

}

Enzyme replacement therapy for lysosomal storage disorder patients. / Hopwood, J.

In: Australian Journal of Medical Science, Vol. 17, No. 4, 1996, p. 157-158.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enzyme replacement therapy for lysosomal storage disorder patients

AU - Hopwood, J.

PY - 1996

Y1 - 1996

N2 - There are 38 known genetic diseases that lead to a breakdown in lysosome function and the pathological storage of substrates in lysosomes. These disorders are known as lysosomal storage disorders (LSD). The importance of LSD to health care becomes obvious when the group incidence rate for LSD (at least 1:5,000) is compared with well-known and intensively studied genetic disorders such as cystic fibrosis (1:2,500) and PKU (1:15,000). All LSD result from a deficiency of enzymes that are involved in the degradation of macromolecules (such as mucopolysaccharides, glycolipids, glycoproteins) or the transport of the products of degradation (such as amino acid, monosaccbarides and inorganic sulphate) out of the lysosome to be recycled. The deficiency of a particular enzyme activity results in lysosomal storage of the substrate for that enzyme. A number of therapies are currently in use or are under evaluation for various LSD types. Bone marrow transplantation has been tried for a number of LSD with some, but limited success. Gene therapy trials for some LSD patients are planned. However, the most effective therapy so far has been enzyme replacement (ERT) for Gaucher disease (a glycolipid LSD). We have been developing ERT for a group of LSD known as the mucopolysaccharidoses (MPS). There are 10 different MPS and we have prepared recombinant enzymes for MPS types I, II, IIIA, IIIB, IIID, IVA and VI. Preliminary results with MPS-VI cats treated with human recombinant N-acetylgalactosamine-4-sulphatase have been most encouraging. We anticipate clinical trials for some of these MPS conditions within a year or two.

AB - There are 38 known genetic diseases that lead to a breakdown in lysosome function and the pathological storage of substrates in lysosomes. These disorders are known as lysosomal storage disorders (LSD). The importance of LSD to health care becomes obvious when the group incidence rate for LSD (at least 1:5,000) is compared with well-known and intensively studied genetic disorders such as cystic fibrosis (1:2,500) and PKU (1:15,000). All LSD result from a deficiency of enzymes that are involved in the degradation of macromolecules (such as mucopolysaccharides, glycolipids, glycoproteins) or the transport of the products of degradation (such as amino acid, monosaccbarides and inorganic sulphate) out of the lysosome to be recycled. The deficiency of a particular enzyme activity results in lysosomal storage of the substrate for that enzyme. A number of therapies are currently in use or are under evaluation for various LSD types. Bone marrow transplantation has been tried for a number of LSD with some, but limited success. Gene therapy trials for some LSD patients are planned. However, the most effective therapy so far has been enzyme replacement (ERT) for Gaucher disease (a glycolipid LSD). We have been developing ERT for a group of LSD known as the mucopolysaccharidoses (MPS). There are 10 different MPS and we have prepared recombinant enzymes for MPS types I, II, IIIA, IIIB, IIID, IVA and VI. Preliminary results with MPS-VI cats treated with human recombinant N-acetylgalactosamine-4-sulphatase have been most encouraging. We anticipate clinical trials for some of these MPS conditions within a year or two.

UR - http://www.scopus.com/inward/record.url?scp=33750161946&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 157

EP - 158

JO - Australian Journal of Medical Science

T2 - Australian Journal of Medical Science

JF - Australian Journal of Medical Science

SN - 1038-1643

IS - 4

ER -